The imatinib‐resistant GIST cell line GIST430/654 (KIT exon 11 delV560‐L576) with a secondary KIT mutation (KIT exon 13 V654) and similar kinetics to GIST882 to induce tumors (Smyth et al., 2012) was used as an imatinib‐resistant model for tumor growth in vivo. This evidence concerns the gene KIT and neoplasm.